×
Hero Background

Cardiomyopathy Medication Companies

ID: MRFR/HC/6784-HCR
111 Pages
Rahul Gotadki
October 2025

Cardiomyopathy refers to diseases of the heart muscle, where the heart becomes enlarged, thickened, or rigid, leading to decreased heart function. Cardiomyopathy medication companies specialize in the research, development, manufacturing, and distribution of pharmaceuticals designed to manage and treat cardiomyopathy. The medications developed by these companies aim to address symptoms, slow the progression of the disease, and improve the quality of life for individuals with cardiomyopathy. 

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Cardiomyopathy Medication Market Research Report - Global Forecast till 2035 Infographic
Summary Table of Contents Segmentation Download PDF

Top Industry Leaders in the Cardiomyopathy Medication Market

Cardiomyopathy Medication Key Companies

 

Latest Cardiomyopathy Medication Companies Update


Cytokinetics (US) Received FDA approval for aficamten (Myodist®), the first FDA-approved medication specifically for hypertrophic cardiomyopathy (HCM).Partnering with healthcare providers to educate clinicians and improve access to aficamten for patients with HCM.


Bristol Myers Squibb (US) Acquired Karuna Therapeutics and RayzeBio to strengthen their neuroscience and oncology portfolios, offering potential benefits for future cardiomyopathy-related drug development.Continued marketing Camzyos (Mavacamten), their FDA-approved medication for symptomatic HCM, focusing on expanding patient access and exploring its use in early-stage disease.


Novartis (Switzerland) Received breakthrough therapy designation for omecamtiv mecarbil (OMT) from the FDA for the treatment of heart failure with preserved ejection fraction (HFpEF).Conducting Phase III clinical trials for OMT, aiming to establish its efficacy and safety as a potential novel treatment option for HFpEF.


Tenaya Therapeutics (US) Initiated Phase IIb clinical trials for levosimendin, a potential treatment for HCM and HFpEF, to evaluate its effectiveness in improving cardiac function and symptoms.Collaborating with research institutions to investigate the underlying mechanisms of cardiomyopathy and identify new therapeutic targets.


American Heart Association (AHA) Updated their guidelines for the management of heart failure, emphasizing personalized treatment plans and including recommendations on novel medication options for specific cardiomyopathy types.Providing educational resources and patient support programs to raise awareness about cardiomyopathy and empower individuals to manage their condition effectively.


List of Cardiomyopathy Medication Key Companies in The Market



  • Pfizer Inc.

  • PhaseBio Pharmaceuticals, Inc.

  • Array Biopharma, Inc.

  • AstraZeneca

  • Sanofi-Aventis US LLC

  • Hoffmann-La Roche Ltd

  • Merck & Co., Inc.

  • Capricor Therapeutics

  • MyoKardia

  • Janssen Products, LP

  • Ionis Pharmaceuticals, Inc.

  • Medtronic

  • Becton And Dickson & Co.

  • Biomerieux

  • Teva Pharmaceutical Industries Ltd